ABT-874 is an investigational drug being tested for psoriasis treatment. In one study, the efficacy and safety of ABT-874 was evaluated in a 52-week randomized, double-blind, placebo-controlled trial in 1,465 patients with moderate to severe psoriasis. At 12 weeks, Physician Global Assessment (PGA) 0/1 (65.9/78.2% vs. 1.3/4.9%) and Psoriasis Activity and Severity Index 75 (PASI 75) were higher for ABT-874 vs. placebo. However, higher incidences of infections and malignancies were reported in ABT-874-treated patients. In a second study, the health-related quality of life (HRQL) of ABT-874 (n = 138) was compared to those of the active comparator etanercept (n = 141) and placebo (n = 68) in a double-blind study. HRQL measurements ...